![Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model - Hájek - 2020 - British Journal of Haematology - Wiley Online Library Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model - Hájek - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a634045e-f2f8-46f7-8089-45a0dcb44c8f/bjh.v190.2.cover.jpg?trick=1678334289385)
Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model - Hájek - 2020 - British Journal of Haematology - Wiley Online Library
Survival Bene t of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refra
![Za své chování se jí přišel omluvit s pugétem. Co na Petra Rychlého prozradila Kateřina Brožová? | tv.blesk.cz Za své chování se jí přišel omluvit s pugétem. Co na Petra Rychlého prozradila Kateřina Brožová? | tv.blesk.cz](https://1884403144.rsc.cdn77.org/foto/ordinace-v-ruzove-zahrade-katerina-brozova-petr-rychly/MTA4MHg2MDgvc21hcnQvZmlsdGVyczpxdWFsaXR5KDgwKS9pbWc/8198553.jpg?v=0&st=XJfIE_2raNDaZtiHEaMlQDdgHS_Dr0ubnxXqxsDZxXw&ts=1600812000&e=0)
Za své chování se jí přišel omluvit s pugétem. Co na Petra Rychlého prozradila Kateřina Brožová? | tv.blesk.cz
![Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients] - ScienceDirect Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients] - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497119709987-gr1.jpg)
Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients] - ScienceDirect
![PDF) Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation PDF) Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation](https://i1.rgstatic.net/publication/319858166_Czech_Registry_of_Monoclonal_Gammopathies_-_Technical_Solution_Data_Collection_and_Visualisation/links/59d0c3c30f7e9b4fd7f9fe0c/largepreview.png)
PDF) Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation
![Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data - Sandecká - 2021 - European Journal of Haematology - Wiley Online Library Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data - Sandecká - 2021 - European Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ad9a6250-b39c-4b14-b5df-692efd7b9f9c/ejh.v107.4.cover.jpg?trick=1678127450830)
Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data - Sandecká - 2021 - European Journal of Haematology - Wiley Online Library
![PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy](https://i1.rgstatic.net/publication/276900159_Subcutaneous_Bortezomib_in_Multiple_Myeloma_Patients_Induces_Similar_Therapeutic_Response_Rates_as_Intravenous_Application_But_It_Does_Not_Reduce_the_Incidence_of_Peripheral_Neuropathy/links/564c99ec08ae3374e5e05406/largepreview.png)
PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
![Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies - Radocha - 2018 - Cancer Medicine - Wiley Online Library Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies - Radocha - 2018 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1700c27e-5153-4918-802e-e76480dc7f31/cam41620-fig-0001-m.jpg)
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies - Radocha - 2018 - Cancer Medicine - Wiley Online Library
![PDF) Analysis of the Phenotype and Function of the Subpopulations of Mucosal‐Associated Invariant T Cells PDF) Analysis of the Phenotype and Function of the Subpopulations of Mucosal‐Associated Invariant T Cells](https://i1.rgstatic.net/publication/305751430_Analysis_of_the_Phenotype_and_Function_of_the_Subpopulations_of_Mucosal-Associated_Invariant_T_Cells/links/5aa4d949aca272d448b905a9/largepreview.png)
PDF) Analysis of the Phenotype and Function of the Subpopulations of Mucosal‐Associated Invariant T Cells
![Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice | BMC Cancer | Full Text Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07732-1/MediaObjects/12885_2020_7732_Fig5_HTML.png)